SCHEMBL4083924

SCHEMBL4083924

O=c1c(-c2ccccc2Cl)cc2cnc(NCC3C4CN(Cc5ccccc5)CC34)nc2n1-c1ccc(F)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 2/20 0.45
TNK2 Q07912 3/20 0.44
FGFR1 P11362 5/20 0.42
PAK1 Q13153 1/20 0.41
SIK1 P57059 1/20 0.41
SIK2 Q9H0K1 1/20 0.41
SIK3 Q9Y2K2 1/20 0.41
FGFR2 P21802 4/20 0.41
MAPK14 Q16539 2/20 0.40
LYN P07948 1/20 0.40
BTK Q06187 1/20 0.40
LCK P06239 1/20 0.40
USP2 O75604 4/20 0.40
ALDH1A1 P00352 4/20 0.40
CYP1A2 P05177 4/20 0.40
CASP1 P29466 4/20 0.40
CASP7 P55210 4/20 0.40
HIF1A Q16665 4/20 0.40
HSD17B10 Q99714 4/20 0.40
MEN1 O00255 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4088404 0.89 MAPK14 (0.45) ABL1TNK2FGFR1PAK1SIK1
SCHEMBL4096767 0.85 MAPK14 (0.46) ABL1TNK2FGFR1PAK1SIK1
SCHEMBL4090415 0.83 MAPK14 (0.46) ABL1TNK2FGFR1PAK1SIK1
SCHEMBL4084520 0.78 MAPK14 (0.49) ABL1TNK2FGFR1PAK1SIK1
SCHEMBL4089659 0.78 MAPK14 (0.49) ABL1TNK2FGFR1PAK1SIK1
SCHEMBL4089107 0.77 MAPK14 (0.46) ABL1TNK2FGFR1PAK1SIK1
SCHEMBL4089687 0.76 MAPK14 (0.41) ABL1TNK2FGFR1PAK1SIK1
SCHEMBL4094749 0.76 MAPK14 (0.48) ABL1TNK2FGFR1PAK1SIK1
SCHEMBL4090598 0.75 MAPK14 (0.47) ABL1TNK2FGFR1PAK1SIK1
SCHEMBL4084691 0.75 MAPK14 (0.44) ABL1TNK2FGFR1PAK1SIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-05-21 US claimed
EP-1831215-A1 PYRIDO[2,3-D]PYRIMIDINES AS ANTI-INFLAMATORY AGENTS Ranbaxy Laboratories Limited (IN) 2007-09-12 EP claimed
WO-2006056863-A1 PYRIDO’2, 3-D!PYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2006-06-01 WO claimed
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-05-21 US disclosed
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-05-21 US disclosed
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-05-21 US disclosed
EP-1831215-A1 PYRIDO[2,3-D]PYRIMIDINES AS ANTI-INFLAMATORY AGENTS Ranbaxy Laboratories Limited (IN) 2007-09-12 EP disclosed
WO-2006056863-A1 PYRIDO’2, 3-D!PYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2006-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS TLR1, TPMT, NOD1 ABL1 3439/4885TNK2 1374/4885FGFR1 1184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.